Insider Transactions in Q3 2025 at Acrivon Therapeutics, Inc. (ACRV)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 21
2025
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,905
-0.93%
|
$19,905
$1.32 P/Share
|
|
Aug 14
2025
|
Eric Devroe Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
613
-0.92%
|
$613
$1.39 P/Share
|
|
Aug 14
2025
|
Erick Gamelin Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
403
-2.5%
|
$403
$1.39 P/Share
|
|
Aug 14
2025
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
184
-0.51%
|
$184
$1.39 P/Share
|
|
Aug 14
2025
|
Katharine Peterson Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-2.29%
|
$99
$1.39 P/Share
|
|
Aug 14
2025
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
490
-0.16%
|
$490
$1.39 P/Share
|
|
Aug 14
2025
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
59,766
-2.71%
|
$59,766
$1.39 P/Share
|
|
Aug 01
2025
|
Adam D. Levy Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,164
-8.74%
|
$1,164
$1.26 P/Share
|
|
Jul 17
2025
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-1.54%
|
$558
$1.32 P/Share
|